An announcement from PainReform ( (PRFX) ) is now available.
On April 7, 2025, PainReform Ltd. provided a year-end business update, highlighting its strategic expansion into the clean energy sector with the acquisition of DeepSolar, an AI-driven solar analytics platform. This move is expected to drive revenue growth and enhance shareholder value. Despite a temporary setback in the Phase 3 clinical trial for PRF-110, the company is addressing data gaps and refining the drug’s pharmacokinetics and pharmacodynamics. Financially, PainReform raised $0.9 million through its ATM program, surpassing Nasdaq’s minimum equity requirement, and reported a net loss of $14.6 million for 2024, with increased R&D expenses due to clinical trial costs.
Spark’s Take on PRFX Stock
According to Spark, TipRanks’ AI Analyst, PRFX is a Underperform.
PainReform faces substantial financial hurdles, primarily due to its lack of revenue and persistent losses, making its financial performance the most significant negative factor. Technical analysis reflects a neutral to slightly bearish outlook, while valuation metrics underscore the company’s financial struggles with a negative P/E ratio. Overall, the stock presents high risks without notable strengths to offset these concerns.
To see Spark’s full report on PRFX stock, click here.
More about PainReform
PainReform is a specialty pharmaceutical company focused on the reformulation of established therapeutics. The company’s proprietary extended-release drug-delivery system aims to provide extended post-surgical pain relief without repeated dosing, reducing the need for opiates. In March 2025, PainReform acquired DeepSolar, an AI-driven solar analytics technology, marking its expansion into the clean energy sector.
YTD Price Performance: -35.49%
Average Trading Volume: 1,125,511
Technical Sentiment Signal: Strong Buy
Current Market Cap: $3.57M
Find detailed analytics on PRFX stock on TipRanks’ Stock Analysis page.